



JOINT TRANSNATIONAL CALL 2017: "Translational Research on Rare Cancers"

PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to

If you have any questions about this form, please do not hesitate to contact us at

Note: Fields marked with a * are mandatory

Contact Information	
First name *	Andreas
Last name *	Scorilas
Position *	Professor
Telephone number	(+30)697 607 2375
E-mail address*	ascorilas@biol.uoa.gr
Website address	http://users.uoa.gr/~ascorilas/
Institution/Organisation *	National and Kapodistrian University of Athens (NKUA)
Department*	Department of Biochemistry and Molecular Biology
Street	Panepistimiopolis
Postal Code / City *	GR-15701, Athens
Country *	GREECE

***I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:**

YES



SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

Project proposal

Project title (draft):

Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words):



OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

Short description of the areas of interest and expertise (Max. 2000 words):

The **Cancer Biomarker Research Unit** (<http://users.uoa.gr/~ascorilas>) in the Department of Biochemistry and Molecular Biology (National and Kapodistrian University of Athens, Athens, Greece) was established by Prof. Andreas Scorilas in 2003. Prof. Scorilas is also the Head of the Department.

The Cancer Biomarker Research Unit is fully equipped with a **next-generation sequencing (NGS) system** (Ion Torrent PGM) for massive parallel high-throughput sequencing approaches, a **pyrosequencer** (PyroMark Q24) for validation analyses, **modern Real-Time PCR instruments** (ABI 7500 and ABI 7500 Fast), **cell culture and radioactivity assay facilities** etc. It also comprises large biobanks of tissue and blood/serum specimens, as well as many human cell lines. Biobanked material consists of patients' samples concerning solid and hematological malignancies, including breast cancer, prostate and bladder urological cancers, cancers of the gastrointestinal tract, head and neck tumors, ovarian cancer and adolescent/childhood leukemias, and non-Hodgkin B-cell lymphomas, completely histologically characterized and accompanied by long-term (>10 years) follow-up. The research group of Dr. Scorilas includes 1 postdoctoral research scientist, 5 PhD candidates, 3 MSc students, 3 undergraduate students, 1 expert in Biostatistics and 1 expert in Bioinformatics (NGS data analysis).

Prof. Scorilas research team's interests include the **discovery and study of novel cancer biomarkers** in the diagnosis, prognosis and treatment monitoring of human malignancies, as well as **the development of highly sensitive molecular methodologies** for the reliable quantification of cancer related genes as well as non-coding RNAs (ncRNAs), including miRNAs and long non-coding RNAs. So far, he has >285 publications in high-impact, international journals (e.g. Journal of Clinical Oncology, Nature Medicine, Cancer Research, Clinical Cancer Research, Clinical Chemistry), with a total Impact Factor >1300 and >11000 citations (h-index>50). He is also inventor in 5 patents and PI on many National, EU and International Research Grants. Last year, he was elected as President of the International Society for Enzymology (ISE).

The collaborating **Cancer Biomarker Research Unit** can **support the development and validation of novel molecular methodologies**:

- a. for ultra-sensitive quantification of protein-coding genes and non-coding RNAs (miRNAs, long non-coding RNAs) expression by real-time quantitative PCR assays,
- b. for high-throughput Next-Generation Sequencing (NGS) applications for genomic, transcriptomic and epigenomic analyses,
- c. combined with extensive Biostatistical and Bioinformatic analyses.